A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Purpose: To determine the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of conatumumab, an investigational, fully human monoclonal agonist antibody against human death receptor 5, in patients with advanced solid tumors. Experimental Design: In the dose-escalation phase, patients received escalating intravenous doses of conatumumab (0.3, 1, 3, 10, or 20 mg/kg, 3–9 per cohort) every 2 weeks. In the dose-expansion phase, 10 patients with colorectal cancer (CRC) and 7 with non–small cell lung cancer (NSCLC) received 20 mg/kg of conatumumab every 2 weeks. Results: Thirty-seven patients received 1 or more doses of conatumumab. Conatumumab seemed to be well tolerated; there were no dose-limiting toxicities. Of adverse events possibly related to treatment, only 3 patients (8%) had a grade 3 event (fatigue and/or elevated lipase), and no anticonatumumab antibodies were detected. An MTD was not reached. Conatumumab exhibited dose linear kinetics from 3 to 20 mg/kg, with a mean terminal half-life of 13 to 19 days. One patient with NSCLC (0.3 mg/kg) had a confirmed partial response (PR) at week 32 (38% reduction in tumor size), with further reduction (48%) by week 96; this patient remains on conatumumab after 4.2 years with a sustained PR. Fourteen patients had a best response of stable disease, 2 for 32 weeks or more. One patient with CRC (0.3 mg/kg) and stable disease for 24 weeks had a 24% reduction in tumor size by RECIST (Response Evaluation Criteria in Solid Tumors) and a 35% reduction in the sum of standardized uptake values of all lesions measured by [18F]fluorodeoxyglucose positron emission tomographic scan. Changes in tumor levels of activated caspase-3 did not appear to be associated with tumor response. Conclusions: Conatumumab can be administered safely up to the target dose of 20 mg/kg every 2 weeks. Clin Cancer Res; 16(23); 5883–91. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Kaplan-Lefko, P. J., Graves, J. D., Zoog, S. J., Pan, Y., Wall, J., Branstetter, D. G., Moriguchi, J., Coxon, A., Huard, J. N., Xu, R., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.8.11264 · Cited by 126
Self-citation
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
Jan, R., & Chaudhry, G.-E.-S. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.024 · Cited by 899
Getting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.81 · Cited by 457
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
Baig, S., Seevasant, I., Mohamad, J., Mukheem, A., Huri, H. Z., & Kamarul, T. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.275 · Cited by 279
Dimberg, L. Y., Anderson, C. K., Camidge, R., Behbakht, K., Thorburn, A., & Ford, H. L. (2013) · Oncogene · doi:10.1038/onc.2012.164 · Cited by 276
Metadata
- Authors
- Herbst, R. S., Kurzrock, R., Hong, D. S., Valdivieso, M., Hsu, C.-P., Goyal, L., Juan, G., Hwang, Y. C., Wong, S., Hill, J. S., Friberg, G., & LoRusso, P. M.
- Venue
- Clinical Cancer Research
- Published
- 2010-12-01
- Volume
- 16
- Issue
- 23
- Pages
- 5883-5891
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2133283258
- Cited by
- 141
- References
- 2
- FWCI
- 11.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-0631
- The paper
- Herbst, R. S., Kurzrock, R., Hong, D. S., Valdivieso, M., Hsu, C.-P., Goyal, L., Juan, G., Hwang, Y. C., Wong, S., Hill, J. S., Friberg, G., & LoRusso, P. M. (2010). A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-0631
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.